+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

High Potency APIs (HPAPIs) - Global Strategic Business Report

  • PDF Icon

    Report

  • 192 Pages
  • March 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 4805562

Global High Potency APIs (HPAPIs) Market to Reach $42.1 Billion by 2030

The global market for High Potency APIs (HPAPIs) estimated at US$21.6 Billion in the year 2022, is projected to reach a revised size of US$42.1 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2022-2030. Innovative, one of the segments analyzed in the report, is projected to record 8.4% CAGR and reach US$28.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Generic segment is readjusted to a revised 9.3% CAGR for the next 8-year period.

The U.S. Market is Estimated at $6.3 Billion, While China is Forecast to Grow at 8.2% CAGR

The High Potency APIs (HPAPIs) market in the U.S. is estimated at US$6.3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$7.3 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.7% and 7.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.8% CAGR.

Select Competitors (Total 38 Featured) -

  • AbbVie, Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • Mylan Pharmaceuticals, Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • High Potency APIs (HPAPIs) - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for High Potency APIs (HPAPIs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 3: World 16-Year Perspective for High Potency APIs (HPAPIs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Innovative by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Innovative by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 6: World 16-Year Perspective for Innovative by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Generic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 9: World 16-Year Perspective for Generic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Captive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Captive by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 12: World 16-Year Perspective for Captive by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Merchant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 14: World Historic Review for Merchant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 15: World 16-Year Perspective for Merchant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 17: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 18: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Hormonal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 20: World Historic Review for Hormonal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 21: World 16-Year Perspective for Hormonal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 22: World Recent Past, Current & Future Analysis for Glaucoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 23: World Historic Review for Glaucoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 24: World 16-Year Perspective for Glaucoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 25: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 26: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 27: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 28: World High Potency APIs (HPAPIs) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • High Potency APIs (HPAPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 29: USA Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 30: USA Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 31: USA 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
  • Table 32: USA Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 33: USA Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 34: USA 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
  • Table 35: USA Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 36: USA Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 37: USA 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
CANADA
  • Table 38: Canada Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 39: Canada Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 40: Canada 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
  • Table 41: Canada Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 42: Canada Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 43: Canada 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
  • Table 44: Canada Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 45: Canada Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 46: Canada 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
JAPAN
  • High Potency APIs (HPAPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 47: Japan Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 48: Japan Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 49: Japan 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
  • Table 50: Japan Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 51: Japan Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 52: Japan 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
  • Table 53: Japan Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 54: Japan Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 55: Japan 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
CHINA
  • High Potency APIs (HPAPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 56: China Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 57: China Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 58: China 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
  • Table 59: China Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 60: China Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 61: China 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
  • Table 62: China Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 63: China Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 64: China 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
EUROPE
  • High Potency APIs (HPAPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 65: Europe Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 66: Europe Historic Review for High Potency APIs (HPAPIs) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 67: Europe 16-Year Perspective for High Potency APIs (HPAPIs) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
  • Table 68: Europe Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 69: Europe Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 70: Europe 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
  • Table 71: Europe Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 72: Europe Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 73: Europe 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
  • Table 74: Europe Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 75: Europe Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 76: Europe 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
FRANCE
  • High Potency APIs (HPAPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 77: France Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 78: France Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 79: France 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
  • Table 80: France Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 81: France Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 82: France 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
  • Table 83: France Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 84: France Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 85: France 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
GERMANY
  • High Potency APIs (HPAPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 86: Germany Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 87: Germany Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 88: Germany 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
  • Table 89: Germany Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 90: Germany Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 91: Germany 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
  • Table 92: Germany Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 93: Germany Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 94: Germany 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
ITALY
  • Table 95: Italy Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 96: Italy Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 97: Italy 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
  • Table 98: Italy Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 99: Italy Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 100: Italy 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
  • Table 101: Italy Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 102: Italy Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 103: Italy 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
UNITED KINGDOM
  • High Potency APIs (HPAPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 104: UK Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 105: UK Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 106: UK 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
  • Table 107: UK Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 108: UK Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 109: UK 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
  • Table 110: UK Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 111: UK Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 112: UK 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
REST OF EUROPE
  • Table 113: Rest of Europe Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 114: Rest of Europe Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 115: Rest of Europe 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
  • Table 116: Rest of Europe Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 117: Rest of Europe Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 118: Rest of Europe 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
  • Table 119: Rest of Europe Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 120: Rest of Europe Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 121: Rest of Europe 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
ASIA-PACIFIC
  • High Potency APIs (HPAPIs) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 122: Asia-Pacific Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Type - Innovative and Generic - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 123: Asia-Pacific Historic Review for High Potency APIs (HPAPIs) by Type - Innovative and Generic Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 124: Asia-Pacific 16-Year Perspective for High Potency APIs (HPAPIs) by Type - Percentage Breakdown of Value Sales for Innovative and Generic for the Years 2014, 2023 & 2030
  • Table 125: Asia-Pacific Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 126: Asia-Pacific Historic Review for High Potency APIs (HPAPIs) by Manufacturer - Captive and Merchant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 127: Asia-Pacific 16-Year Perspective for High Potency APIs (HPAPIs) by Manufacturer - Percentage Breakdown of Value Sales for Captive and Merchant for the Years 2014, 2023 & 2030
  • Table 128: Asia-Pacific Recent Past, Current & Future Analysis for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
  • Table 129: Asia-Pacific Historic Review for High Potency APIs (HPAPIs) by Application - Oncology, Hormonal Disorders, Glaucoma and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 130: Asia-Pacific 16-Year Perspective for High Potency APIs (HPAPIs) by Application - Percentage Breakdown of Value Sales for Oncology, Hormonal Disorders, Glaucoma and Other Applications for the Years 2014, 2023 & 2030
REST OF WORLDIV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie, Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • Mylan Pharmaceuticals, Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.

Table Information